EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Temporal Profile of Hypofibrinogenemia and Related Coagulation Abnormalities in Patients Receiving Eravacycline: A Retrospective Cohort Study

Yanduan Lin, Ye Li, Anqi Li, Haiyan Mai, Jing Liu, Lejia Xu

Drugs - Real World Outcomes · 17.11.2026

DOI: 10.1007/s40801-026-00580-8 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Drugs - Real World Outcomes, online erschienen am 17.11.2026. Verfasst von Yanduan Lin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Third Affiliated Hospital of Sun Yat-Sen University, Guangdong, 510630, Guangzhou, People's Republic of China. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Eravacycline is a novel tetracycline antibiotic approved for complicated intraabdominal infections. Recent reports have suggested a potential association with hypofibrinogenemia, but real-world data are limited.

Objective

The purpose of this study was to investigate the temporal profile and associated coagulation abnormalities of hypofibrinogenemia in patients receiving eravacycline in a real-world cohort.

Methods

A retrospective observational study was conducted on patients who received eravacycline treatment at a tertiary care center from December 2023 to December 2025. Clinical data of the enrolled patients were collected, and the incidence of hypofibrinogenemia occurring during eravacycline therapy was calculated. The clinical characteristics of patients with hypofibrinogenemia were summarized.

Results

Among the 31 patients who received eravacycline for at least 72 h, 7 patients (22.6%) experienced a decline in blood fibrinogen levels (fibrinogen < 2.0 g/L). The median time to the first detected decrease in fibrinogen levels was 4 days, and the median time to nadir was 8 days among affected patients. Fibrinogen decline during eravacycline therapy is frequently accompanied by d -dimer elevation and thrombocytopenia.

Conclusions

There was a temporal association between eravacycline exposure and fibrinogen decline, which was typically observed within the first week of therapy and was frequently accompanied by d -dimer elevation.

Autor:innen und Institutionen

  • Department of Pharmacy, Third Affiliated Hospital of Sun Yat-Sen University, Guangdong, 510630, Guangzhou, People's Republic of China.
  • Department of Infectious Diseases, Third Affiliated Hospital of Sun Yat-Sen University, Guangdong, 510630, Guangzhou, People's Republic of China. liuj26@mail.sysu.edu.cn.
  • Department of Pharmacy, Third Affiliated Hospital of Sun Yat-Sen University, Guangdong, 510630, Guangzhou, People's Republic of China. xulejia@mail.sysu.edu.cn.

Zitieren

APA

Lin, Y., Li, Y., Li, A., Mai, H., Liu, J., & Xu, L. (2026). Temporal Profile of Hypofibrinogenemia and Related Coagulation Abnormalities in Patients Receiving Eravacycline: A Retrospective Cohort Study. Drugs - Real World Outcomes. https://doi.org/10.1007/s40801-026-00580-8

Vancouver

Lin Y, Li Y, Li A, Mai H, Liu J, Xu L. Temporal Profile of Hypofibrinogenemia and Related Coagulation Abnormalities in Patients Receiving Eravacycline: A Retrospective Cohort Study. Drugs - Real World Outcomes. 2026. doi:10.1007/s40801-026-00580-8

BibTeX
@article{Lin2026,
  author = {Lin, Yanduan and Li, Ye and Li, Anqi and Mai, Haiyan and Liu, Jing and Xu, Lejia},
  title = {Temporal Profile of Hypofibrinogenemia and Related Coagulation Abnormalities in Patients Receiving Eravacycline: A Retrospective Cohort Study},
  journal = {Drugs - Real World Outcomes},
  year = {2026},
  doi = {10.1007/s40801-026-00580-8}
}
Kostenlos starten →